TD-1607
/ Theravance Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 20, 2021
Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates.
(PubMed, Front Chem)
- "The multi-targeted TD-1792, for instance, retained potent antibacterial activities against multiple strains that are resistant to its constituent, vancomycin...DSTA4637S is a pioneer antibacterial agent under clinical development and represents a novel class of bacterial therapy, that is, antibody-antibiotic conjugates. DSTA4637S is effective against the notorious persistent S. aureus bacteremia, a revelation of the abracadabra potential of antibiotic hybrid approaches."
Clinical • Journal • Review • Infectious Disease
1 to 1
Of
1
Go to page
1